読み込み中
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
前日終値
$2.66
−$0.05 · -1.85%
日中の時刻はETです。市場データは遅延する場合があります。
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
日中レンジ
現在 $2.66
52週レンジ
現在 $2.66
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
14
著しい割高
センチメント
48
まちまち
リスク
75
高リスク
モメンタム
34
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
日中レンジ
現在 $2.66
52週レンジ
現在 $2.66
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | 145.4万 USD | 143.4万 USD | 541.5万 USD | 1079.5万 USD |
| 売上原価 | — | 230.6万 USD | — | 304.8万 USD | 617.9万 USD |
| 粗利益 | — | −85.2万 USD | 143.4万 USD | 236.7万 USD | 461.6万 USD |
| 研究開発 | 8421.5万 USD | 3933.2万 USD | 2131.1万 USD | 181.3万 USD | 258.2万 USD |
| 販売・一般管理 | 3023.3万 USD | 2661.3万 USD | 2106.4万 USD | 935.2万 USD | 942.5万 USD |
| 営業費用 | 1.14億 USD | 6594.5万 USD | 4237.5万 USD | 1147万 USD | 1200.7万 USD |
| 受取利息 | 811.4万 USD | 1051.5万 USD | 93.4万 USD | 112.2万 USD | 11.9万 USD |
| 支払利息 | 37.6万 USD | 4.8万 USD | 8.4万 USD | — | — |
| 減価償却費と償却費 | 325.1万 USD | 230.6万 USD | 98.6万 USD | 32.4万 USD | 24.8万 USD |
| 営業利益 | −1.14億 USD | −6679.7万 USD | −4094.1万 USD | −910.3万 USD | −739.1万 USD |
| 純利益 | −1.03億 USD | −7927.9万 USD | −4650.8万 USD | −1076万 USD | −727.2万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$11.00
上昇余地（313.53%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2024年6月17日 | 1:10 | — | — |
株式分割 | 2005年8月17日 | 1:30 | — | — |
株式分割 | 1988年7月6日 | 1:20 | — | — |
発効済み 2024年6月17日
1:10
発効済み 2005年8月17日
1:30
発効済み 1988年7月6日
1:20
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1046.93万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM733.13万0.01%782.66億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF312.38万0.00%954億 USD0.05%$235+0.80%
iShares Biotechnology ETFIBB189.21万0.02%102.79億 USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO187.17万0.01%180億 USD0.06%$112.66+0.50%
Dimensional - US Small Cap ETFDFAS162.54万0.00%338.69億 USD0.31%$78.35+0.32%
Schwab U.S. Small-Cap ETFSCHA125.69万0.01%218.24億 USD0.03%$32.79+0.40%
Vanguard Health Care ETFVHT88.74万0.00%220億 USD0.09%$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
